CHRONIC MYELOGENOUS LEUKEMIA
Clinical trials for CHRONIC MYELOGENOUS LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new CHRONIC MYELOGENOUS LEUKEMIA trials appear
Sign up with your email to follow new studies for CHRONIC MYELOGENOUS LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo pill shows promise for stubborn leukemia
Disease control CompletedThis phase 2 trial tested whether adding asciminib to the standard drug imatinib helps people with chronic myeloid leukemia (CML) achieve deeper remission. 104 adults who had been on imatinib for at least a year without reaching very low cancer levels were randomly assigned to ad…
Matched conditions: CHRONIC MYELOGENOUS LEUKEMIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Cord blood boost: new technique shows promise for tough leukemia cases
Disease control CompletedThis study tested a new way to prepare cord blood for transplant in 30 people with high-risk leukemia or myelodysplasia. The cord blood was treated with a molecule called UM171 to help it grow more stem cells. The goal was to see if this approach is safe and helps patients recove…
Matched conditions: CHRONIC MYELOGENOUS LEUKEMIA
Phase: PHASE2 • Sponsor: ExCellThera inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for leukemia patients: asciminib shows promise in phase 3 trial
Disease control CompletedThis study tested the drug asciminib in 199 adults with chronic myeloid leukemia (CML) whose cancer was not well controlled after trying at least two other targeted therapies. The main goal was to see how many patients achieved a major molecular response (a key sign of disease co…
Matched conditions: CHRONIC MYELOGENOUS LEUKEMIA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Half-Matched stem cell transplant shows promise for older blood cancer patients
Disease control CompletedThis study tested a stem cell transplant from half-matched (haploidentical) family donors for 34 people with various blood cancers. Patients received a reduced-intensity conditioning regimen of fludarabine, melphalan, and total body irradiation before the transplant. The goal was…
Matched conditions: CHRONIC MYELOGENOUS LEUKEMIA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New chemo combo before donor transplant shows promise for leukemia patients
Disease control CompletedThis study tested adding a drug called thiotepa to the usual chemotherapy given before a donor stem cell transplant for people with leukemia. The goal was to see if this stronger mix could help more patients stay cancer-free one year after the transplant. The study included 40 ad…
Matched conditions: CHRONIC MYELOGENOUS LEUKEMIA
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug combo may make bone marrow transplants safer for blood cancer patients
Disease control CompletedThis early-phase trial tested replacing the standard drug cyclophosphamide with bendamustine after a half-matched bone marrow transplant in 50 patients with various blood cancers. The goal was to see if this change could reduce side effects like graft-versus-host disease while st…
Matched conditions: CHRONIC MYELOGENOUS LEUKEMIA
Phase: PHASE1 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Can a cheaper, easier drug keep CML at bay after stronger treatment?
Disease control CompletedThis study looked at whether people with chronic myeloid leukemia (CML) who had a good response to the drug nilotinib could switch to imatinib to maintain that response. The goal was to see if imatinib could keep the cancer under control while being easier to take and less expens…
Matched conditions: CHRONIC MYELOGENOUS LEUKEMIA
Phase: NA • Sponsor: American University of Beirut Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Leukemia drug holiday: study tests if patients can pause nilotinib
Disease control CompletedThis study looked at whether people with chronic myeloid leukemia (CML) who have done very well on the drug nilotinib can safely stop taking it. 215 patients who had been on nilotinib for at least two years and had very low levels of cancer cells were enrolled. The main goal was …
Matched conditions: CHRONIC MYELOGENOUS LEUKEMIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 15:56 UTC